+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)

RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)

Clinical Calcium 21(8): 1239-1247

Treatment for cancer may cause gonadal dysfunction and bone loss (cancer treatment-induced bone loss ; CTIBL) . Especially, endocrine therapies for breast cancer or prostate cancer carry a significant risk of CTIBL. Therapy-induced premature menopause in premenopausal breast cancer patients, aromatase inhibitor in postmenopausal breast cancer patients, and LHRH agonist with or without anti-androgen in prostate cancer patients may cause bone loss of 5% or more. RANKL (receptor activator of nuclear factor-κB ligand) antibody (denosumab) is effective for prevention of CTIBL and it may prevent CTIBL-induced fracture. During cancer treatment with gonadal dysfunction, bone mineral density should be carefully followed to avoid QOL impairment due to osoteoporosis.

(PDF emailed within 1 workday: $29.90)

Accession: 055333155

Download citation: RISBibTeXText

PMID: 21814031

Related references

Bone and calcium metabolism associated with malignancy. Clinical Characteristics and Treatment of Cancer Treatment Induced Bone Loss(CTIBL)in Breast Cancer. Clinical Calcium 28(11): 1515-1517, 2018

Cancer Treatment-Induced Bone Loss(CTIBL). Gan to Kagaku Ryoho. Cancer & ChemoTherapy 45(12): 1685-1689, 2018

Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid. European Urology Supplements 3(5): 46-54, 2004

Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treatment Reviews 41(9): 798-808, 2016

Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL. Clinical Calcium 21(3): 447-453, 2011

Prostate cancer and Cancer Treatment-Induced Bone Loss(CTIBL). Clinical Calcium 26(7): 1039-1045, 2016

Can an annual infusion of zoledronic acid protect against cancer-treatment induced bone loss (CTIBL)?. Journal of Clinical Oncology 23(16_suppl): 8023-8023, 2016

Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial. Journal of Clinical Oncology 23(16_suppl): 533-533, 2016

The mechanism of anti-RANKL antibody in the treatment of metabolic bone diseases including osteoporosis - possible applications of anti-RANKL antibody to the treatment of cancer patients. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 153(1): 11-15, 2019

Cancer treatment-induced bone less (CTIBL) in prostate cancer: Pathophysiology, preclinical findings, and treatment with zoledronic acid. European Urology Supplements 3(5): 46-54, 2004

AMG-162. Treatment of osteoporosis bone cancer therapy treatment of rheumatoid arthritis human anti-RANKL monoclonal antibody. Drugs of the Future 30(3): 237-239, 2005

Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 39(1): 89-94, 2012

Topical Treatment with Xiaozheng Zhitong Paste (XZP) Alleviates Bone Destruction and Bone Cancer Pain in a Rat Model of Prostate Cancer-Induced Bone Pain by Modulating the RANKL/RANK/OPG Signaling. Evidence-Based Complementary and Alternative Medicine 2015: 215892-215892, 2015

Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochemical and Biophysical Research Communications 347(1): 124-132, 2006

A new vaccine targeting RANKL, prepared by incorporation of an unnatural Amino acid into RANKL, prevents OVX-induced bone loss in mice. Biochemical and Biophysical Research Communications: -, 2018